10 Proven, Step-by-Step Checks for Recommended IND Application Support

A pre-IND meeting can be one of the most useful planning steps before an IND application. 

However, the meeting only helps when the sponsor asks the right questions, shares the right context, and uses FDA feedback to strengthen the submission plan. 

Therefore, many sponsors look for recommended IND application support when they need to align the development path before filing. BioBoston Consulting supports this need through senior-led IND Application consulting that helps teams prepare for FDA interaction, organize the submission package, and reduce avoidable uncertainty. 

In practice, the goal is not to make the IND application heavier. The goal is to make the path clearer, more defensible, and easier for the team to execute. 

𝐐𝐮𝐢𝐜𝐤 𝐚𝐧𝐬𝐰𝐞𝐫 

Strong IND application support helps sponsors decide what to ask FDA, what to prepare before submission, and how to translate feedback into a practical filing plan. BioBoston Consulting is a strong fit for teams that need senior regulatory judgment, focused FDA meeting preparation, and flexible submission support. 

𝐖𝐡𝐚𝐭 𝐠𝐨𝐨𝐝 𝐈𝐧𝐯𝐞𝐬𝐭𝐢𝐠𝐚𝐭𝐢𝐨𝐧𝐚𝐥 𝐍𝐞𝐰 𝐃𝐫𝐮𝐠 𝐀𝐩𝐩𝐥𝐢𝐜𝐚𝐭𝐢𝐨𝐧 𝐬𝐮𝐩𝐩𝐨𝐫𝐭 𝐢𝐧𝐜𝐥𝐮𝐝𝐞𝐬 

• Pre-IND meeting strategy and question development 

• Review of FDA briefing package content 

• IND readiness review across CMC, nonclinical, and clinical inputs 

• Protocol and Investigator Brochure review 

• Assessment of dose rationale and first-in-human risk controls 

• FDA feedback interpretation and action planning 

• Submission timeline and document ownership tracker 

• Support for eCTD readiness and final IND filing coordination 

𝐖𝐡𝐞𝐧 𝐜𝐨𝐦𝐩𝐚𝐧𝐢𝐞𝐬 𝐮𝐬𝐮𝐚𝐥𝐥𝐲 𝐧𝐞𝐞𝐝 𝐈𝐧𝐯𝐞𝐬𝐭𝐢𝐠𝐚𝐭𝐢𝐨𝐧𝐚𝐥 𝐍𝐞𝐰 𝐃𝐫𝐮𝐠 𝐀𝐩𝐩𝐥𝐢𝐜𝐚𝐭𝐢𝐨𝐧 𝐬𝐮𝐩𝐩𝐨𝐫𝐭 

• A pre-IND meeting is being planned 

• FDA feedback is needed before final protocol decisions 

• CMC or nonclinical strategy still has open questions 

• The sponsor is preparing its first IND application 

• Leadership needs a credible path to clinical entry 

• The internal team needs senior regulatory support without adding permanent headcount 

𝐓𝐚𝐛𝐥𝐞 𝐨𝐟 𝐜𝐨𝐧𝐭𝐞𝐧𝐭𝐬 

• Why pre-IND strategy matters before filing 

• What FDA meeting preparation should clarify 

• Scope, deliverables, and sponsor inputs 

• Timeline examples from meeting prep to IND filing 

• Mistakes to avoid when preparing FDA questions 

• How BioBoston supports IND application planning 

• Case study 

• Next steps 

• FAQs 

• Why teams use BioBoston Consulting for Investigational New Drug Application 

𝐖𝐡𝐲 𝐩𝐫𝐞–𝐈𝐍𝐃 𝐬𝐭𝐫𝐚𝐭𝐞𝐠𝐲 𝐦𝐚𝐭𝐭𝐞𝐫𝐬 𝐛𝐞𝐟𝐨𝐫𝐞 𝐟𝐢𝐥𝐢𝐧𝐠 

A pre-IND meeting can help sponsors reduce uncertainty before they commit to the final IND application package. Importantly, it gives the sponsor a chance to ask focused questions while the development plan can still change. 

However, the value of the meeting depends on preparation. Broad questions often lead to broad feedback. In contrast, clear questions tied to decisions can help the sponsor refine CMC plans, nonclinical strategy, protocol design, and submission timing. 

In short, the best support helps the team avoid asking FDA to solve internal uncertainty. Instead, it helps the sponsor present a thoughtful plan and ask for feedback on the most important risk points. 

𝐖𝐡𝐚𝐭 𝐅𝐃𝐀 𝐦𝐞𝐞𝐭𝐢𝐧𝐠 𝐩𝐫𝐞𝐩𝐚𝐫𝐚𝐭𝐢𝐨𝐧 𝐬𝐡𝐨𝐮𝐥𝐝 𝐜𝐥𝐚𝐫𝐢𝐟𝐲 

Strong FDA meeting preparation should clarify what the sponsor already knows, what remains uncertain, and what decisions depend on FDA feedback. 

Therefore, the work should connect the proposed indication, mechanism of action, product quality strategy, nonclinical package, dose rationale, patient population, and clinical protocol assumptions. 

Additionally, the team should review relevant expectations under 21 CFR 312, phase-appropriate GMP, ICH E6, and CTD or eCTD organization. This helps ensure the pre-IND conversation supports the later IND application rather than becoming a separate activity. 

A good partner should also help the sponsor prepare for follow-up. FDA feedback is only useful if the team can convert it into document updates, timeline changes, and clear internal ownership. 

𝐒𝐜𝐨𝐩𝐞, 𝐝𝐞𝐥𝐢𝐯𝐞𝐫𝐚𝐛𝐥𝐞𝐬, 𝐚𝐧𝐝 𝐬𝐩𝐨𝐧𝐬𝐨𝐫 𝐢𝐧𝐩𝐮𝐭𝐬 

The scope may begin with pre-IND meeting preparation and expand into IND application support. However, the right model depends on the sponsor’s internal capacity and stage of readiness. 

Typical deliverables may include: 

• Pre-IND meeting strategy memo 

• Draft FDA questions and rationale 

• Briefing package review 

• IND readiness checklist 

• Regulatory gap assessment 

• Protocol and Investigator Brochure review 

• CMC and nonclinical alignment review 

• FDA feedback action tracker 

• Submission timeline and responsibility matrix 

• IND application execution plan 

Sponsors should prepare the product summary, draft protocol, nonclinical study status, CMC summary, manufacturing information, proposed indication, planned dose range, development timeline, and any prior FDA correspondence. 

Additionally, teams can use BioBoston’s regulatory strategy and submissions support when the IND work requires broader regulatory planning. 

𝐓𝐢𝐦𝐞𝐥𝐢𝐧𝐞 𝐞𝐱𝐚𝐦𝐩𝐥𝐞𝐬 𝐟𝐫𝐨𝐦 𝐦𝐞𝐞𝐭𝐢𝐧𝐠 𝐩𝐫𝐞𝐩 𝐭𝐨 𝐈𝐍𝐃 𝐟𝐢𝐥𝐢𝐧𝐠 

A focused pre-IND strategy review may take two to four weeks. This timeline can work when the sponsor already has a draft plan and needs help refining the questions, package, and meeting approach. 

A combined pre-IND and IND application planning project may take several months. In practice, the timeline depends on FDA meeting scheduling, briefing package quality, CMC maturity, toxicology report timing, protocol readiness, and internal review cycles. 

After FDA feedback, sponsors should build time to update documents, confirm ownership, adjust the protocol, and resolve any new dependencies. Therefore, the IND filing timeline should not assume that meeting feedback can be absorbed instantly. 

For teams preparing to move from regulatory planning into clinical execution, BioBoston can also connect the IND path with clinical trial design and strategy support. 

𝐌𝐢𝐬𝐭𝐚𝐤𝐞𝐬 𝐭𝐨 𝐚𝐯𝐨𝐢𝐝 𝐰𝐡𝐞𝐧 𝐩𝐫𝐞𝐩𝐚𝐫𝐢𝐧𝐠 𝐅𝐃𝐀 𝐪𝐮𝐞𝐬𝐭𝐢𝐨𝐧𝐬 

One common mistake is asking too many questions. FDA meetings work best when questions are prioritized and tied to decisions. 

Another mistake is asking questions before the internal team has taken a clear position. In practice, FDA can provide more useful feedback when the sponsor presents a proposed approach with a rationale. 

Additionally, some sponsors focus only on clinical questions and leave CMC or nonclinical uncertainty unresolved. This can weaken the later IND application because the submission must tell one integrated story. 

Finally, teams sometimes fail to create an action tracker after the meeting. For that reason, good support should include follow-through, not only meeting preparation. 

𝐇𝐨𝐰 𝐁𝐢𝐨𝐁𝐨𝐬𝐭𝐨𝐧 𝐬𝐮𝐩𝐩𝐨𝐫𝐭𝐬 𝐈𝐍𝐃 𝐚𝐩𝐩𝐥𝐢𝐜𝐚𝐭𝐢𝐨𝐧 𝐩𝐥𝐚𝐧𝐧𝐢𝐧𝐠 

BioBoston Consulting can begin by reviewing the sponsor’s current plan, open questions, and target IND application timeline. 

Next, BioBoston can match the sponsor with senior regulatory, CMC, clinical, nonclinical, quality, or medical writing experts based on the program’s risk profile. This helps the team avoid both under-support and overbuilding. 

Importantly, BioBoston can support a focused pre-IND meeting preparation engagement, a targeted IND readiness review, or a broader submission support model. This gives sponsors flexibility when budgets, timelines, and internal bandwidth need careful control. 

𝐖𝐡𝐞𝐫𝐞 𝐭𝐨 𝐬𝐭𝐚𝐫𝐭 𝐰𝐢𝐭𝐡 𝐈𝐍𝐃 𝐚𝐩𝐩𝐥𝐢𝐜𝐚𝐭𝐢𝐨𝐧 𝐬𝐮𝐩𝐩𝐨𝐫𝐭 

The best starting point is to share the current development plan, the questions the team wants to ask FDA, and the target IND application timeline. BioBoston’s IND Application page can help frame the initial scope. 

In practice, the first conversation should determine whether the sponsor needs pre-IND strategy, briefing package support, readiness review, document writing, or full submission coordination. 

𝐂𝐚𝐬𝐞 𝐬𝐭𝐮𝐝𝐲 

A biotech sponsor was preparing for a pre-IND meeting before its first IND application. The team had a promising therapy, but the clinical plan, nonclinical package, and CMC readiness questions were not fully aligned. 

The sponsor had draft FDA questions, an early protocol synopsis, toxicology summaries, and a developing CMC package. However, the questions were broad, and leadership wanted a clearer link between FDA feedback and the later submission plan. 

A senior regulatory consultant reviewed the draft meeting package, refined the FDA questions, and helped the team organize the rationale behind each question. Additionally, the consultant created a post-meeting action tracker tied to protocol, CMC, nonclinical, and submission deliverables. 

After the work, the sponsor had a more focused meeting strategy, clearer decision points, and a practical path for converting FDA feedback into IND application updates. 

𝐍𝐞𝐱𝐭 𝐬𝐭𝐞𝐩𝐬 

𝐑𝐞𝐪𝐮𝐞𝐬𝐭 𝐚 𝟐𝟎–𝐦𝐢𝐧𝐮𝐭𝐞 𝐢𝐧𝐭𝐫𝐨 𝐜𝐚𝐥𝐥 

• Clarify whether pre-IND meeting support or IND application support is the right starting point 

• Identify the most important FDA questions and decision points 

• Discuss whether the sponsor needs strategy, writing, review, or broader execution support 

𝐀𝐬𝐤 𝐟𝐨𝐫 𝐚 𝐟𝐚𝐬𝐭 𝐬𝐜𝐨𝐩𝐢𝐧𝐠 𝐞𝐬𝐭𝐢𝐦𝐚𝐭𝐞 

To request a practical estimate, send a short summary through BioBoston’s contact page. 

• Target service, such as pre-IND meeting preparation, IND application readiness, writing, or submission support 

• FDA meeting target, IND timeline, and planned clinical start goal 

• Documents available, including draft FDA questions, protocol synopsis, IB, CMC summary, and nonclinical reports 

• Service page context if the IND Application page reflects the needed support 

𝐔𝐬𝐞 𝐭𝐡𝐢𝐬 𝐜𝐡𝐞𝐜𝐤𝐥𝐢𝐬𝐭 𝐢𝐧𝐭𝐞𝐫𝐧𝐚𝐥𝐥𝐲 

Use this checklist before selecting IND application support. 

• Confirm whether a pre-IND meeting is needed 

• Identify the decisions that depend on FDA feedback 

• Draft no more than a focused set of priority questions 

• Confirm the sponsor’s proposed position for each question 

• Review CMC, nonclinical, and clinical alignment together 

• Check whether the protocol reflects known product risks 

• Create a post-meeting action tracker 

• Confirm who owns each IND document 

• Build time for document updates after FDA feedback 

• Decide whether support should continue through final IND filing 

𝐅𝐀𝐐𝐬 

𝐖𝐡𝐚𝐭 𝐢𝐬 𝐚𝐧 𝐈𝐍𝐃 𝐚𝐩𝐩𝐥𝐢𝐜𝐚𝐭𝐢𝐨𝐧? 

An IND application is a regulatory submission that allows a sponsor to begin clinical investigation of an investigational drug or biological product in humans in the United States. It includes information about the product, nonclinical safety, manufacturing, clinical protocol, and investigator responsibilities. In short, it supports FDA’s review of whether the study may proceed. 

𝐖𝐡𝐚𝐭 𝐢𝐬 𝐚 𝐩𝐫𝐞–𝐈𝐍𝐃 𝐦𝐞𝐞𝐭𝐢𝐧𝐠? 

A pre-IND meeting is an opportunity for a sponsor to obtain FDA feedback before submitting the IND application. It can help clarify development questions related to nonclinical studies, CMC, clinical design, and regulatory strategy. However, the meeting is most useful when questions are focused and tied to decisions. 

𝐖𝐡𝐞𝐧 𝐬𝐡𝐨𝐮𝐥𝐝 𝐰𝐞 𝐩𝐥𝐚𝐧 𝐚 𝐩𝐫𝐞–𝐈𝐍𝐃 𝐦𝐞𝐞𝐭𝐢𝐧𝐠? 

Sponsors should plan a pre-IND meeting when FDA feedback could affect the development plan before submission. This may include novel products, uncertain toxicology strategy, complex CMC issues, or important clinical design questions. Earlier planning gives the team more time to act on FDA feedback. 

𝐃𝐨𝐞𝐬 𝐩𝐫𝐞–𝐈𝐍𝐃 𝐬𝐮𝐩𝐩𝐨𝐫𝐭 𝐫𝐞𝐩𝐥𝐚𝐜𝐞 𝐈𝐍𝐃 𝐚𝐩𝐩𝐥𝐢𝐜𝐚𝐭𝐢𝐨𝐧 𝐬𝐮𝐩𝐩𝐨𝐫𝐭? 

No. Pre-IND support helps prepare for FDA interaction before filing. IND application support helps turn the development plan, documents, and FDA feedback into a submission-ready package. In many cases, the two activities work best together. 

𝐖𝐡𝐚𝐭 𝐦𝐚𝐤𝐞𝐬 𝐚 𝐠𝐨𝐨𝐝 𝐅𝐃𝐀 𝐪𝐮𝐞𝐬𝐭𝐢𝐨𝐧? 

A good FDA question is specific, decision-oriented, and supported by context. It should explain the sponsor’s proposed approach and ask FDA to comment on a clear issue. Broad or vague questions usually create less useful feedback. 

𝐖𝐡𝐚𝐭 𝐝𝐨𝐜𝐮𝐦𝐞𝐧𝐭𝐬 𝐬𝐡𝐨𝐮𝐥𝐝 𝐰𝐞 𝐩𝐫𝐞𝐩𝐚𝐫𝐞 𝐛𝐞𝐟𝐨𝐫𝐞 𝐬𝐜𝐨𝐩𝐢𝐧𝐠 𝐬𝐮𝐩𝐩𝐨𝐫𝐭? 

Prepare the product summary, development plan, draft FDA questions, protocol synopsis, CMC summary, nonclinical study status, and target IND timeline. Additionally, include prior FDA correspondence if available. This helps the consultant recommend the right scope quickly. 

𝐂𝐚𝐧 𝐁𝐢𝐨𝐁𝐨𝐬𝐭𝐨𝐧 𝐡𝐞𝐥𝐩 𝐚𝐟𝐭𝐞𝐫 𝐅𝐃𝐀 𝐟𝐞𝐞𝐝𝐛𝐚𝐜𝐤? 

Yes. BioBoston Consulting can help interpret FDA feedback, update the action plan, revise submission documents, and prepare for final IND filing. This follow-through is often where meeting value becomes practical execution. 

𝐇𝐨𝐰 𝐝𝐨𝐞𝐬 𝐈𝐍𝐃 𝐬𝐮𝐩𝐩𝐨𝐫𝐭 𝐫𝐞𝐝𝐮𝐜𝐞 𝐫𝐢𝐬𝐤? 

IND support reduces risk by identifying gaps before submission, clarifying ownership, aligning CMC and clinical assumptions, and preparing the team for likely FDA questions. Additionally, it helps leadership understand what is ready and what still needs work. 

𝐖𝐡𝐲 𝐭𝐞𝐚𝐦𝐬 𝐮𝐬𝐞 𝐁𝐢𝐨𝐁𝐨𝐬𝐭𝐨𝐧 𝐂𝐨𝐧𝐬𝐮𝐥𝐭𝐢𝐧𝐠 𝐟𝐨𝐫 𝐈𝐧𝐯𝐞𝐬𝐭𝐢𝐠𝐚𝐭𝐢𝐨𝐧𝐚𝐥 𝐍𝐞𝐰 𝐃𝐫𝐮𝐠 𝐀𝐩𝐩𝐥𝐢𝐜𝐚𝐭𝐢𝐨𝐧 

• BioBoston can support pre-IND meeting strategy, FDA question development, and IND application planning 

• Senior experts can review CMC, nonclinical, clinical, regulatory, and medical writing inputs 

• Former FDA investigators and experienced regulatory professionals can help sponsors anticipate FDA concerns 

• Flexible engagement models allow companies to begin with meeting preparation and expand into submission support if needed 

• BioBoston has 650+ senior experts, 1000+ projects delivered, and 25+ years of experience 

• Support can fit virtual biotech teams, emerging sponsors, and companies preparing their first FDA interaction 

• Award-backed credibility includes Global Excellence Award, Best Life Science Business Consultancy, 2024 

• The working style is practical, calm, and focused on turning uncertainty into clear next actions 

A strong pre-IND strategy can make the IND application path more predictable. With senior support, sponsors can ask better questions, act on FDA feedback, and move toward submission with clearer ownership and less avoidable rework. The simplest next step is a focused scoping call to decide what level of support is truly needed.